XML 21 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current Assets:    
Cash and cash equivalents $ 128,994 $ 322,536
Marketable securities 213,591  
Accounts receivable, net of reserves of $5,128 in 2015 and $4,306 in 2014 188,318 152,380
Inventories 188,833 160,342
Deferred income tax assets 39,829 37,689
Other current assets 62,069 86,451
Total current assets 821,634 759,398
Long-Term Assets:    
Property and equipment, net 333,026 303,587
Goodwill 178,934 184,450
Intangible assets, net 55,909 65,122
Other long-term assets 85,490 71,654
Total long-term assets 653,359 624,813
TOTAL ASSETS 1,474,993 1,384,211
Current Liabilities:    
Accounts payable 52,648 44,743
Accrued liabilities 205,530 195,351
Line of credit 573,000 549,000
Current portion of deferred revenue 25,583 31,812
Total current liabilities 856,761 820,906
Long-Term Liabilities:    
Deferred income tax liabilities 49,389 41,688
Long-term debt 597,085 350,000
Long-term deferred revenue, net of current portion 27,055 21,665
Other long-term liabilities 28,698 32,363
Total long-term liabilities 702,227 445,716
Total liabilities $ 1,558,988 $ 1,266,622
Commitments and Contingencies (Note 14)
Stockholders’ Equity (Deficit):    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 102,237 and 101,947 shares in 2015 and 2014, respectively $ 10,258 $ 10,195
Additional paid-in capital 940,534 888,293
Deferred stock units: Outstanding: 240 and 235 units in 2015 and 2014, respectively 5,409 5,066
Retained earnings 318,356 1,675,299
Accumulated other comprehensive loss (42,265) (8,071)
Treasury stock, at cost: 12,242 and 54,574 shares in 2015 and 2014, respectively (1,316,417) (2,453,266)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit) (84,125) 117,516
Noncontrolling interest 130 73
Total stockholders’ equity (deficit) (83,995) 117,589
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) $ 1,474,993 $ 1,384,211